Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D04WFL
|
||||
| Former ID |
DAP000391
|
||||
| Drug Name |
Trastuzumab
|
||||
| Synonyms |
Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Approved | [1], [2], [3] | ||
| Therapeutic Class |
Anticancer Agents
|
||||
| Company |
Roche; Genentech
|
||||
| Formula |
C6470H10012N1726O2013S42
|
||||
| CAS Number |
CAS 180288-69-1
|
||||
| PubChem Substance ID | |||||
| SuperDrug ATC ID |
L01XC03
|
||||
| SuperDrug CAS ID |
cas=180288691
|
||||
| Drug Resistance Mutation (DRM) | |||||
| DRM | DRM Info | ||||
| Target and Pathway | |||||
| Target(s) | Erbb2 tyrosine kinase receptor (HER2) | Target Info | . | [4], [5], [6] | |
| KEGG Pathway | ErbB signaling pathway | ||||
| Calcium signaling pathway | |||||
| HIF-1 signaling pathway | |||||
| Focal adhesion | |||||
| Adherens junction | |||||
| Pathways in cancer | |||||
| Proteoglycans in cancer | |||||
| MicroRNAs in cancer | |||||
| Pancreatic cancer | |||||
| Endometrial cancer | |||||
| Prostate cancer | |||||
| Bladder cancer | |||||
| Non-small cell lung cancer | |||||
| Central carbon metabolism in cancer | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| Panther Pathway | Cadherin signaling pathway | ||||
| EGF receptor signaling pathway | |||||
| Pathwhiz Pathway | Phosphatidylinositol Phosphate Metabolism | ||||
| Pathway Interaction Database | ErbB4 signaling events | ||||
| ErbB2/ErbB3 signaling events | |||||
| ErbB receptor signaling network | |||||
| a6b1 and a6b4 Integrin signaling | |||||
| Validated targets of C-MYC transcriptional repression | |||||
| Reactome | SHC1 events in ERBB2 signaling | ||||
| PLCG1 events in ERBB2 signaling | |||||
| PIP3 activates AKT signaling | |||||
| GRB2 events in ERBB2 signaling | |||||
| PI3K events in ERBB2 signaling | |||||
| Constitutive Signaling by Aberrant PI3K in Cancer | |||||
| Sema4D induced cell migration and growth-cone collapse | |||||
| RAF/MAP kinase cascade | |||||
| WikiPathways | DNA Damage Response (only ATM dependent) | ||||
| ErbB Signaling Pathway | |||||
| EGF/EGFR Signaling Pathway | |||||
| Focal Adhesion | |||||
| Extracellular vesicle-mediated signaling in recipient cells | |||||
| Bladder Cancer | |||||
| Signaling by ERBB2 | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| Signaling Pathways in Glioblastoma | |||||
| Leptin signaling pathway | |||||
| miR-targeted genes in muscle cell - TarBase | |||||
| Semaphorin interactions | |||||
| References | |||||
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5082). | ||||
| REF 2 | Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. | ||||
| REF 3 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | ||||
| REF 4 | Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10. | ||||
| REF 5 | Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51. | ||||
| REF 6 | Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines. Cancer Immunol Immunother. 2002 Jan;50(11):569-87. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.